There are currently 48 clinical trials in Irving, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University Hills Clinical Research, Pfizer Investigational Site, GSK Investigational Site and Novo Nordisk Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT05787587
Recruiting
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: NEXT Oncology, Irving, Texas
Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
Register for Updates
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: NEXT Oncology Dallas, Irving, Texas
Conditions: Advanced Solid Malignancies
Register for Updates
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934
Recruiting
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/03/2024
Locations: Research Site, Irving, Texas
Conditions: ER-Positive HER2-Negative Breast Cancer
Register for Updates
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062
Recruiting
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The first three subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel
Gender:
All
Ages:
18 years and above
Trial Updated:
05/30/2024
Locations: NEXT Oncology Dallas, Irving, Texas
Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
NCT05935098
Recruiting
This study aims to test the safety, tolerability, and preliminary anti-tumor activity of BGB-A3055, either alone or in combination with Tislelizumab in participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Next Dallas, Irving, Texas
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
Register for Updates
Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658
Recruiting
This is a first-in-human (FIH), open label Phase 1/1b study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs. Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and evaluate inci... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: NEXT Oncology, Irving, Texas
Conditions: Cancer
Register for Updates
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
NCT06326047
Recruiting
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/27/2024
Locations: Tekton Research, Irving, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266
Recruiting
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
05/27/2024
Locations: Research Site, Irving, Texas
Conditions: NSCLC
Register for Updates
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505
Recruiting
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients rece... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Next Oncology Dallas, Irving, Texas
Conditions: Ovarian Cancer, Non-small Cell Lung Cancer
Register for Updates
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
NCT05227690
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/22/2024
Locations: Irving, Texas, Irving, Texas
Conditions: Schizophrenia
Register for Updates
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/22/2024
Locations: University Hills Clinical Research, Irving, Texas
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Arizona Oncology NAHOA, Irving, Texas +8 locations
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates